Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 4, 2013, Pages 524-531

  Sowa Staszczak, Anna ^a   Pach, Dorota ^a   Mikołajczak, Renata ^b   Mäcke, Helmut ^c   Jabrocka Hybel, Agata ^a   Stefańska, Agnieszka ^a   Tomaszuk, Monika ^a   Janota, Barbara ^b   Gilis Januszewska, Aleksandra ^a   Małecki, Maciej ^a   Kamiński, Grzegorz ^d   Kowalska, Aldona ^e   Kulig, Jan ^a   Matyja, Andrzej ^a   Osuch, Czesław ^a   Hubalewska Dydejczyk, Alicja ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b NATIONAL CENTRE FOR NUCLEAR RESEARCH   (Poland)

^c UNIVERSITY OF FREIBURG   (Germany)

^d MILITARY INSTITUTE OF MEDICINE   (Poland)

^e Holycross Cancer Center   (Poland)

Author keywords

GLP 1; Imaging; Insulinoma; Labelled peptides

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID EXENDIN 4 INDIUM IN 111; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULINOMA; INTESTINE; KIDNEY; LIVER; MALE; MUSCLE; NATIONAL HEALTH ORGANIZATION; OVARY; PANCREAS; RADIATION DOSE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; THYROID GLAND;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; HYDRAZINES; HYPOGLYCEMIC AGENTS; INSULINOMA; MALE; MIDDLE AGED; NICOTINIC ACIDS; ORGANOTECHNETIUM COMPOUNDS; PANCREATIC NEOPLASMS; PEPTIDES; RADIOPHARMACEUTICALS; RECEPTORS, GLUCAGON; VENOMS; YOUNG ADULT;

EID: 84875745842     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2299-1     Document Type: Article

References (29)

1. Ehehalt F, Saeger HD, Schmidt CM, Grützmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009;14:456-67.
2. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005;19:783-98.
3. Sotoudehmanesh R, Hedayat A, Shirazian N, Shahraeeni S, Ainechi S, Zeinali F, et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine. 2007;31:238-41.
4. Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN. Pancreatic insulinoma: current issues and trends. Hepatobiliary Pancreat Dis Int 2010;9:234-41.
5. Nöldge G, Weber MA, Ritzel RA, Werner MJ, Kauczor HU, Grenacher L. Invasive diagnostic procedures for insulinomas of the pancreas. Radiologe 2009;49:224-32.
6. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma - incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991;66:711-9.
7. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-93.
8. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003;88:5353-60.
9. Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008;359:766-8.
10. Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, et al. Glucagon-like peptide 1-receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009;94:4398-405.
11. Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 2010;51:1059-67.
12. Janota B, Jakubowska E, Leszczynska M, et al. [Lys40-(Ahx-HYNIC)NH2- 99mTc]exendin-4 as potential radiopharmaceutical for insulinoma diagnostics. Eur J Nucl Med Mol Imaging 2011;38(Suppl 2):S242.
13. Hubalewska-Dydejczyk A, Fröss-Baron K, Mikołajczak R, Maecke HR, Huszno B, Pach D, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123-33.
14. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Mays MT, Koral KF, et al. MIRD pamphlet no.16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61.
15. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no.21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med 2009;50:477-84.
16. Synder WS, Ford MR, Warner GG, et al. MIRD pamphlet no. 11:, "S," absorbed dose per unit cumulated activity for selected radionuclides and organs. New York: Society of Nuclear Medicine; 1975.
17. International Commission on Radiological Protection (ICRP). The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37:1-332.
18. Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G, EANM Dosimetry Committee. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 2010;37:1238-50.
19. Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brändle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011;52:1073-8.
20. Reubi JC, Kvols L, Krenning E, Lamberts SW. In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncol 1991;30:463-8.
21. Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol 2012;212:49-60.
22. Rumilla KM, Erickson LA, Service FJ, Vella A, Thompson GB, Grant CS, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis: histologic features and growth factor expression. Mod Pathol 2009;22:239-45.
23. Reubi JC, Perren A, Rehmann R, Waser B, Christ E, Callery M, et al. Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass. Diabetologia 2010;53:2641-5.
24. Bright E, Garcea G, Ong S, Madira W, Berry DP, Dennison AR. An unusual case of concurrent insulinoma and nesidioblastosis. JOP 2008;9:649-53.
25. Vegt E, Eek A, Oyen WJG, de Jong M, Gotthardt M, Boerman OC. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2010;37:226-34.
26. Brom M, Oyen WJG, Joosten L, Gotthardt M, Boerman OC. 68Ga-Labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010;37:1345-55.
27. Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage EN, et al. PET of insulinoma using 18F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm 2011;8:1775-82.
28. González-Vázquez A, Ferro-Flores G, Arteaga de Murphy C, Gutiérrez-García Z. Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits. Appl Radiat Isot 2006;64:792-7.
29. Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, et al. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors. J Nucl Med 2011;52:1474-81.